Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment

Cancer Immunology, Immunotherapy

Volumn 61, Issue 1, 2012, Pages 49-61

  Wang, Shangzi ^a   Astsaturov, Igor A ^b   Bingham, Catherine A ^b   McCarthy, Kenneth M ^b   Von Mehren, Margaret ^b   Xu, Wei ^a   Alpaugh, R Katherine ^b   Tang, Yong ^a   Littlefield, Bruce A ^c,d   Hawkins, Lynn D ^c   Ishizaka, Sally T ^c   Weiner, Louis M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c EISAI RESEARCH INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antibody therapy; Antitumor immunity; HER2; Toll like receptor 4 agonist; Transgenic mouse

Indexed keywords

E 6020; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HOST RESISTANCE; IMMUNOLOGICAL TOLERANCE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; RECEPTOR, ERBB-2; TOLL-LIKE RECEPTOR 4;

EID: 84856705455     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1090-7     Document Type: Article

References (35)

1. P McLaughlin AJ Grillo-Lopez BK Link R Levy MS Czuczman ME Williams MR Heyman I Bence-Bruckler CA White F Cabanillas V Jain AD Ho J Lister K Wey D Shen BK Dallaire 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 16 8 2825 2833 9704735 1:CAS:528:DyaK1cXlsFCgu7c%3D (Pubitemid 28363048)
2. MS Kaminski J Estes KR Zasadny IR Francis CW Ross M Tuck D Regan S Fisher J Gutierrez S Kroll R Stagg G Tidmarsh RL Wahl 2000 Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 96 4 1259 1266 10942366 1:CAS:528:DC%2BD3cXlvF2it7k%3D (Pubitemid 30658452)
3. LM Weiner AS Belldegrun J Crawford AW Tolcher P Lockbaum RH Arends L Navale RG Amado G Schwab RA Figlin 2008 Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies Clin Cancer Res 14 2 502 508 18223225 10.1158/1078-0432.CCR-07-1509 1:CAS:528:DC%2BD1cXhtVKhsrY%3D (Pubitemid 351226119)
4. D Cunningham Y Humblet S Siena D Khayat H Bleiberg A Santoro D Bets M Mueser A Harstrick C Verslype I Chau E Van Cutsem 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 337 345 15269313 10.1056/NEJMoa033025 1:CAS:528: DC%2BD2cXlvFGitbk%3D (Pubitemid 38944402)
5. JG Egen MS Kuhns JP Allison 2002 CTLA-4: new insights into its biological function and use in tumor immunotherapy Nat Immunol 3 7 611 618 12087419 10.1038/ni0702-611 1:CAS:528:DC%2BD38Xksl2mtbs%3D (Pubitemid 34752469)
6. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 4 443 446 10742152 10.1038/74704 1:CAS:528:DC%2BD3cXisVOru7Y%3D (Pubitemid 30208162)
7. V Minard-Colin Y Xiu JC Poe M Horikawa CM Magro Y Hamaguchi KM Haas TF Tedder 2008 Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV Blood 112 4 1205 1213 18495955 10.1182/blood-2008-01-135160 1:CAS:528:DC%2BD1cXpvVOktrc%3D
8. G Cartron L Dacheux G Salles P Solal-Celigny P Bardos P Colombat H Watier 2002 Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene Blood 99 3 754 758 11806974 10.1182/blood.V99.3.754 1:CAS:528:DC%2BD38XhtVals7k%3D (Pubitemid 34525533)
9. WK Weng R Levy 2003 Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 21 3940 3947 12975461 10.1200/JCO.2003.05. 013 1:CAS:528:DC%2BD2cXpsVajsb8%3D (Pubitemid 46606207)
10. H Borghaei RK Alpaugh P Bernardo IE Palazzo JP Dutcher U Venkatraj WC Wood L Goldstein LM Weiner 2007 Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group J Immunother 30 4 455 467 17457220 10.1097/CJI.0b013e31803bb421 1:CAS:528:DC%2BD2sXksFOltrw%3D (Pubitemid 46684435)
11. C Taylor D Hershman N Shah N Suciu-Foca DP Petrylak R Taub L Vahdat B Cheng M Pegram KL Knutson R Clynes 2007 Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy Clin Cancer Res 13 17 5133 5143 17785568 10.1158/1078-0432.CCR-07-0507 1:CAS:528:DC%2BD2sXpvFGqsrk%3D (Pubitemid 47502081)
12. S Park Z Jiang ED Mortenson L Deng O Radkevich-Brown X Yang H Sattar Y Wang NK Brown M Greene Y Liu J Tang S Wang YX Fu 2010 The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity Cancer Cell 18 2 160 170 20708157 10.1016/j.ccr.2010.06.014 1:CAS:528:DC%2BC3cXhtVejs7vF
13. AL Gilman MF Ozkaynak KK Matthay M Krailo AL Yu J Gan A Sternberg JA Hank R Seeger GH Reaman PM Sondel 2009 Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group J Clin Oncol 27 1 85 91 19047298 10.1200/JCO.2006.10.3564 1:CAS:528:DC%2BD1MXhs1Gnsb0%3D
14. LM Weiner Z Steplewski H Koprowski S Litwin RL Comis 1988 Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes Cancer Res 48 4 1042 1046 3123051 1:STN:280:DyaL1c7gvFegtQ%3D%3D (Pubitemid 18061909)
15. JP Leonard BK Link C Emmanouilides SA Gregory D Weisdorf J Andrey J Hainsworth JA Sparano DE Tsai S Horning AM Krieg GJ Weiner 2007 Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma Clin Cancer Res 13 20 6168 6174 17947483 10.1158/1078-0432.CCR-07-0815 1:CAS:528:DC%2BD2sXhtFygsL7E (Pubitemid 350075077)
16. MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 9 2639 2648 10561337 1:CAS:528:DyaK1MXmtlWrurk%3D (Pubitemid 29415219)
17. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 3 719 726 11821453 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D (Pubitemid 34111379)
18. S Cooley LJ Burns T Repka JS Miller 1999 Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu Exp Hematol 27 10 1533 1541 10517495 10.1016/S0301-472X(99)00089-2 1:CAS:528: DyaK1MXmslWmtbk%3D (Pubitemid 29458428)
19. E Stocklin F Botteri B Groner 1993 An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice J Cell Biol 122 1 199 208 8100231 10.1083/jcb.122.1.199 1:STN:280:DyaK3szgtV2jsA%3D%3D (Pubitemid 23188811)
20. D Finkle ZR Quan V Asghari J Kloss N Ghaboosi E Mai WL Wong P Hollingshead R Schwall H Koeppen S Erickson 2004 HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice Clin Cancer Res 10 7 2499 2511 15073130 10.1158/1078-0432.CCR-03-0448 1:CAS:528:DC%2BD2cXivFSqsbw%3D (Pubitemid 38445712)
21. MP Piechocki YS Ho S Pilon WZ Wei 2003 Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines J Immunol 171 11 5787 5794 14634087 1:CAS:528:DC%2BD3sXptFOksr4%3D (Pubitemid 37467194)
22. ST Ishizaka LD Hawkins 2007 E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant Expert Rev Vaccines 6 5 773 784 17931157 10.1586/14760584.6.5.773 1:CAS:528:DC%2BD2sXhtFGgsrrO (Pubitemid 47607852)
23. LD Hawkins ST Ishizaka P McGuinness H Zhang W Gavin B DeCosta Z Meng H Yang M Mullarkey DW Young DP Rossignol A Nault J Rose M Przetak JC Chow F Gusovsky 2002 A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity J Pharmacol Exp Ther 300 2 655 661 11805229 10.1124/jpet.300.2.655 1:CAS:528:DC%2BD38Xos12jtw%3D%3D (Pubitemid 34106260)
24. M Przetak J Chow H Cheng J Rose LD Hawkins ST Ishizaka 2003 Novel synthetic LPS receptor agonists boost systemic and mucosal antibody responses in mice Vaccine 21 9-10 961 970 12547609 10.1016/S0264-410X(02)00737-5 1:CAS:528:DC%2BD3sXltlSntQ%3D%3D (Pubitemid 36126431)
25. GL Morefield LD Hawkins ST Ishizaka TL Kissner RG Ulrich 2007 Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome Clin Vaccine Immunol 14 11 1499 1504 17715328 10.1128/CVI.00153-07 1:CAS:528:DC%2BD2sXhtl2nurbJ (Pubitemid 350304045)
26. BC Baudner V Ronconi D Casini M Tortoli J Kazzaz M Singh LD Hawkins A Wack DT O'Hagan 2009 MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020) Pharm Res 26 6 1477 1485 19255727 10.1007/s11095-009-9859-5 1:CAS:528:DC%2BD1MXisFWns7g%3D
27. LM Weiner MV Dhodapkar S Ferrone 2009 Monoclonal antibodies for cancer immunotherapy Lancet 373 9668 1033 1040 19304016 10.1016/S0140-6736(09)60251-8 1:CAS:528:DC%2BD1MXjsVOnt7g%3D
28. LM Weiner R Surana S Wang 2010 Monoclonal antibodies: versatile platforms for cancer immunotherapy Nat Rev Immunol 10 5 317 327 20414205 10.1038/nri2744 1:CAS:528:DC%2BC3cXltV2kurg%3D
29. PS Kim TD Armstrong H Song ME Wolpoe V Weiss EA Manning LQ Huang S Murata G Sgouros LA Emens RT Reilly EM Jaffee 2008 Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs J Clin Invest 118 5 1700 1711 18398507 10.1172/JCI34333 1:CAS:528:DC%2BD1cXlsF2ntLs%3D (Pubitemid 351632374)
30. L Apetoh F Ghiringhelli A Tesniere M Obeid C Ortiz A Criollo G Mignot MC Maiuri E Ullrich P Saulnier H Yang S Amigorena B Ryffel FJ Barrat P Saftig F Levi R Lidereau C Nogues JP Mira A Chompret V Joulin F Clavel-Chapelon J Bourhis F Andre S Delaloge T Tursz G Kroemer L Zitvogel 2007 Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat Med 13 9 1050 1059 17704786 10.1038/nm1622 1:CAS:528: DC%2BD2sXhtVSgtr3E (Pubitemid 47517504)
31. L Bevaart MJ Jansen MJ van Vugt JS Verbeek JG van de Winkel JH Leusen 2006 The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma Cancer Res 66 3 1261 1264 16452176 10.1158/0008-5472.CAN-05-2856 1:CAS:528:DC%2BD28XpsVejtg%3D%3D (Pubitemid 43259901)
32. JE Wooldridge Z Ballas AM Krieg GJ Weiner 1997 Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma Blood 89 8 2994 2998 9108420 1:STN:280: DyaK2s3mt1SjtA%3D%3D (Pubitemid 27172587)
33. D Rittirsch MA Flierl DE Day BA Nadeau FS Zetoune JV Sarma CM Werner GA Wanner HP Simmen MS Huber-Lang PA Ward 2009 Cross-talk between TLR4 and FcgammaReceptorIII (CD16) pathways PLoS Pathog 5 6 e1000464 19503602 10.1371/journal.ppat.1000464
34. YM Saenger Y Li KC Chiou B Chan G Rizzuto SL Terzulli T Merghoub AN Houghton JD Wolchok 2008 Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma Cancer Res 68 23 9884 9891 19047169 10.1158/0008-5472.CAN-08-2233 1:CAS:528:DC%2BD1cXhsVegtbnJ
35. EV Schmidt G Christoph R Zeller P Leder 1990 The cytomegalovirus enhancer: a pan-active control element in transgenic mice Mol Cell Biol 10 8 4406 4411 2164640 1:CAS:528:DyaK3cXkvFakt7c%3D